ISRCTN52623943已完成未知
High Dose Therapy in Poor-Risk Primary Breast Cancer
Amgen Limited (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Complete prior resection of tumour and axillary node clearance
- •2. Histologically proven T1-T4 primary breast cancer with at least four involved nodes in the axilla
- •3. Adequate local therapy as defined in the protocol
- •4. Aged <60 years
- •5. No previous malignancy or evidence of metastatic disease
- •6. Fit to receive treatment
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
Epirubicin/Paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) as adjuvant chemotherapy in high-risk patients with operable breast cancerCancer - BreastBreast CancerACTRN12615000161527Hellenic Cooperative Oncology Group1,000
已完成
不适用
Investigation of the prognostic role of protein expression, mRNA levels, gene amplification and mutation of key cellular elements in patients with breast cancer treated with dose-dense sequential adjuvant chemotherapyCancer - BreastBreast CancerACTRN12616001043426Hellenic Cooperative Oncology Group1,060
已完成
3 期
Epirubicin-Paclitaxel-Cyclophosphamide Methotrexate Fluorouracil (E-T-CMF) versus Epirubicin-Cyclophosphamide Methotrexate Fluorouracil (E-CMF) as adjuvant chemotherapy in high risk patients with operable breast cancer. A phase III study conducted by the Hellenic Cooperative Oncology Group (HE10/97)ACTRN12611000506998Hellenic Cooperative Oncology Group600
招募中
2 期
Partial Breast Radiotherapy in Low-risk Breast cancer group using a stereotactic MR-guided adaptive approach; a phase II studybreast cancerNL-OMON45437Vrije Universiteit Medisch Centrum50
招募中
不适用
Partial Breast Radiotherapy in Low-risk Breast cancer group using a MR-guided adaptive approach; a phase II studyBreast cancerNL-OMON26191Amsterdam UMC, location VUmc50